
Precipio PRPO
$ 24.93
-1.85%
Annual report 2025
added 03-30-2026
Precipio Total Assets 2011-2026 | PRPO
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Precipio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.3 M | 17 M | 18.1 M | 21.5 M | 30.4 M | 20.7 M | 19.5 M | 21.6 M | 27.3 M | 1.26 M | 4.82 M | 30 M | 30.3 M | 38.8 M | 33.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 38.8 M | 1.26 M | 22.4 M |
Quarterly Total Assets Precipio
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.2 M | 18.8 M | 17.8 M | 17 M | 17 M | 17.3 M | 16.6 M | 18.1 M | 19.1 M | 19.5 M | 19.4 M | 21.5 M | 23.5 M | 26 M | 28 M | 30.4 M | 31.6 M | 33.5 M | 20.4 M | 20.7 M | 20.7 M | 20.7 M | 20.7 M | 19.5 M | 19.5 M | 19.5 M | 19.5 M | 21.6 M | 21.6 M | 21.6 M | 21.6 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 842 K | 842 K | 842 K | 1.26 M | 4.82 M | 4.82 M | 4.82 M | 4.82 M | 30 M | 30 M | 30 M | 30 M | 30.3 M | 30.3 M | 30.3 M | 30.3 M | 38.8 M | 38.8 M | 38.8 M | 38.8 M | 33.6 M | 33.6 M | 33.6 M | 33.6 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 38.8 M | 842 K | 22.5 M |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
10.7 B | $ 114.84 | -0.55 % | $ 34.9 B | ||
|
Aspira Women's Health
AWH
|
5.46 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | ||
|
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M | ||
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M | ||
|
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | ||
|
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | ||
|
Exact Sciences Corporation
EXAS
|
5.86 B | - | - | $ 19.8 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | ||
|
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | ||
|
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | ||
|
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | ||
|
QIAGEN N.V.
QGEN
|
6.28 B | - | - | $ 10.6 B | ||
|
Anixa Biosciences
ANIX
|
16.1 M | $ 2.59 | 1.37 % | $ 84.1 K | ||
|
Biodesix
BDSX
|
97.2 M | $ 15.32 | 1.66 % | $ 1.99 B | ||
|
Biomerica
BMRA
|
5.94 M | $ 2.17 | - | $ 4.98 M | ||
|
BioNano Genomics
BNGO
|
73.6 M | $ 1.19 | -1.25 % | $ 6.48 M | ||
|
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 16.57 | 2.28 % | $ 178 M | ||
|
CareDx, Inc
CDNA
|
413 M | $ 18.37 | 0.33 % | $ 979 M | ||
|
Celcuity
CELC
|
467 M | $ 113.92 | 1.14 % | $ 5.33 B | ||
|
Co-Diagnostics
CODX
|
24.7 M | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | ||
|
Charles River Laboratories International
CRL
|
7.14 B | $ 167.82 | -3.49 % | $ 8.32 B | ||
|
Castle Biosciences
CSTL
|
531 M | $ 24.95 | 0.44 % | $ 693 M | ||
|
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 198.98 | 0.92 % | $ 22.1 B | ||
|
Danaher Corporation
DHR
|
83.5 B | $ 191.91 | 0.41 % | $ 137 B | ||
|
DexCom
DXCM
|
6.34 B | $ 63.19 | 1.56 % | $ 24.7 B | ||
|
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | ||
|
Fulgent Genetics
FLGT
|
1.22 B | $ 16.66 | -0.95 % | $ 504 M | ||
|
Guardant Health
GH
|
2.01 B | $ 90.61 | -3.44 % | $ 11.4 B | ||
|
ICON Public Limited Company
ICLR
|
16.9 B | $ 111.56 | -2.31 % | $ 9.2 B | ||
|
Interpace Biosciences
IDXG
|
33.8 M | $ 1.96 | 5.82 % | $ 8.67 M | ||
|
Illumina
ILMN
|
6.3 B | $ 128.04 | 0.52 % | $ 20.4 B | ||
|
IQVIA Holdings
IQV
|
29.9 B | $ 171.32 | -1.12 % | $ 29.4 B | ||
|
Invitae Corporation
NVTA
|
1.95 B | - | - | $ 21.2 M | ||
|
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 275.75 | 0.74 % | $ 22.9 B | ||
|
Lantheus Holdings
LNTH
|
2.23 B | $ 76.36 | 0.35 % | $ 5.15 B | ||
|
Medpace Holdings
MEDP
|
1.98 B | $ 490.0 | -1.67 % | $ 14.1 B | ||
|
Organovo Holdings
ONVO
|
14.6 M | - | -2.3 % | $ 19.4 M | ||
|
OpGen
OPGN
|
9.86 M | - | -16.95 % | $ 1.54 M | ||
|
Mettler-Toledo International
MTD
|
3.71 B | $ 1 257.33 | -0.21 % | $ 25.9 B | ||
|
Myriad Genetics
MYGN
|
707 M | $ 4.78 | 0.63 % | $ 443 M | ||
|
ENDRA Life Sciences
NDRA
|
3.85 M | $ 4.51 | -3.84 % | $ 3.55 M | ||
|
NeoGenomics
NEO
|
1.36 B | $ 8.0 | - | $ 1.02 B |